Aura Biosciences, Inc. (AURA) SEC Filings & Earnings Calls

Deprioritization of NMIBC program reduces pipeline diversification; reliance on ocular oncology for future value.

“minimizing resource allocation toward the NMIBC program on a going forward basis.” · word for word

Workforce reduction may impact morale and execution capability.

“reduce its workforce by approximately 20%.” · word for word

Single product candidate dependency

“We are heavily dependent on the success of belzupacap sarotalocan, or bel-sar, our only product candidate to date.” · word for word

Clinical trial failure risk

“We have completed enrollment in our pivotal Phase 3 clinical trial, but we do not expect topline data until the second half of 2027, and we have not yet completed such trial nor commercialized any pharmaceutical products.” · word for word

Need for additional capital

“The future viability of the Company beyond that point is dependent on its ability to raise additional capital to finance its operations.” · word for word

Regulatory approval uncertainty

“If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals for bel-sar, we will not be able to commercialize, or will be delayed in commercializing, our product candidates.” · word for word

No material risks identified from this routine board appointment.

“Standard director appointment and compensation policy amendment.”

Dilution risk from authorized share increase

“Future issuances of common stock or securities convertible into common stock could have a dilutive effect on the earnings per share, book value per share, voting power and percentage interest of holdings of current stockholders.” · word for word

CEO transition risk

“Dr. Elisabet de los Pinos resigned as our Chief Executive Officer and President effective as of April 30, 2026.” · word for word

Activist exit / loss of large shareholder support

“This Amendment No. 4 is the final amendment to the Schedule 13D and constitutes an "exit filing" for the Reporting Persons.” · word for word

Clinical trial risk; Phase 3 data not expected until 2H 2027.

“Topline data from CoMpass trial anticipated in second half of 2027.”

Increased net loss and operating expenses may pressure cash runway if milestones slip.

“Net loss increased to $33.7M; R&D and G&A expenses rising.”

Pre-revenue clinical-stage biotechnology company with history of losses

“We have incurred significant net losses since our inception and anticipate that we will continue to incur losses for the foreseeable future.” · word for word

Single product candidate dependency

“We are heavily dependent on the success of belzupacap sarotalocan, or bel-sar, our only product candidate to date.” · word for word

Need for additional capital beyond 12 months

“The future viability of the Company beyond that point is dependent on its ability to raise additional capital to finance its operations.” · word for word

Activist exit / loss of large shareholder support

“This Amendment No. 4 is the final amendment to the Schedule 13D and constitutes an "exit filing" for the Reporting Persons.” · word for word

Dilution from large equity offering

“Issued 39.591M shares plus pre-funded warrants for 3.8M shares and underwriter option for 6.509M shares”

Founder departure may signal strategic shift; new CEO's compensation includes large equity grant.

“Dr. Elisabet de los Pinos, founder, departed as CEO and director.”

Repurchase is contingent on closing of equity offering; may not occur

“We cannot provide any assurance that the Stock Repurchase will occur on the terms described herein, or at all” · word for word

Related party transaction with Matrix Capital (10.8% holder) requires audit committee approval

“reviewed and approved by the audit committee... composed of three independent directors who are not affiliated with Matrix” · word for word

Concentrated ownership and board change

“Matrix Capital Management Master Fund, LP 6,922,870 shares, 10.8% ... Karan Takhar, a current Class II director, will not stand for reelection”

No specific financial metrics disclosed in excerpt; reliance on forward-looking statements about clinical trials and regulatory approvals.

“Forward-looking statements about initiation, timing, progress, results, and cost of R&D programs.”

Going concern risk

“Based on our current operating plan, we believe there is substantial doubt about our ability to continue as a going concern for at least twelve months following the filing of this Annual Report on Form 10-K, and we will need to obtain additional funding.” · word for word

Single product dependency

“We are heavily dependent on the success of bel-sar, our only product candidate to date.” · word for word

Regulatory approval risk for combination product

“Because the activity of bel-sar in ocular melanoma requires a drug delivery device and activation by a laser, the regulatory complexity of the product candidate is greater than for products that do not utilize a device, which creates uncertainties in the requirements for regulatory approval.” · word for word

Clinical trial enrollment delays in rare disease indication

“Enrollment has taken longer than expected in early choroidal melanoma due to requirement to document active tumor growth and other unique enrollment challenges.”

No revenue, pre-commercialization

“We have incurred significant net losses since our inception and anticipate that we will continue to incur losses for the foreseeable future.” · word for word

Single product candidate dependency

“We are heavily dependent on the success of belzupacap sarotalocan, or bel-sar, our only product candidate to date.” · word for word

Need for additional capital

“The future viability of the Company beyond that point is dependent on its ability to raise additional capital to finance its operations.” · word for word